ANZCTR search results

The purpose of this study was to understand how accurately surgical ward round patient case notes are. This was achieved by comparing audio-visual recordings of the ward round, to patient case notes. The hypothesis of this study is that ward round case notes are accurate and capture what is discussed in the ward round.

The study is designed to identify patients from different hospital departments who have been admitted to the Transplant unit, the ICU and/or Outpatients Department, suspected of having a Blood Stream Infection (BSI) and/or an invasive fungal infection. Clinical assessment of patients eligible to be enrolled in this study will be conducted by the department physicians. Study subjects will have blood samples collected for blood culture (standard of care/SOC), as well as an additional blood EDTA tube, and/or bronchiolar lavage and/or sputum samples collected at the same time. These samples will be processed using the Microbio InfectID assay in an experienced diagnostic laboratory. Diagnostic accuracy will be calculated with respect to the SOC blood culture and other culture-based test results.

We are conducting a pilot study to see how well a cardiac rehabilitation program helps patients recover after open heart surgery. We will use the Duke Activity Status Index (DASI) tool to measure how much the program improves your ability to perform daily activities. This study aims to gather early information to understand how cardiac rehabilitation might help patients get better after their surgery. We are also interested in learning about the recovery of patients who choose not to participate in a cardiac rehabilitation program. This will help us compare the outcomes of those who do and do not participate in the rehabilitation program.

This is a randomised controlled trial to evaluate the acceptability, feasibility, and potential efficacy of a novel web-based electronic point-of-care tool, "e-HANDI," to facilitate GPs' prescription and patients' use of effective NDIs in primary care. e-HANDI is a web-based user-centred point-of-care tool that is systematically developed from the bottom-up to facilitate easier, practical prescribing of NDIs in primary care.

The aim of this study is to determine the Optimal Biological Dose, and Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of Actinium (225Ac) Ibu-DAB-PSMA for the Treatment of PSMA-positive Progressive Metastatic Castration Resistant Prostate Cancer Who is it for? You may be eligible for this study if you are a Male participant aged at least 18 years have a histologically, pathologically, and/or cytologically confirmed metastatic adenocarcinoma of the prostate without significant sarcomatoid or spindle or neuroendocrine or small cell differentiation components. Stage IV prostate cancer with at least one lesion that is measurable on baseline CT or MRI, or present on bone scan imaging, obtained within 30 days prior to trial enrolment. At least one PSMA PET/CT positive lesion (i.e., higher than liver uptake) within 30 days prior to enrolment. Study details Participants will receive different numbers of doses in cycles (two, three, or six), which will test 3 different dose levels/strengths of ITM-22. Participants will then be tested for optimal biological dose, tolerability and safety, preliminary efficacy signals of actinium, pharmacokinetics and biomarkers. It is hoped that findings from this study will demonstrate that actinium (225Ac) Ibu-DAB-PSMA is safe and well tolerated by patients with progressive mCRPC. The results in this study will determine the optimal biological dose for expansion of the trial in phase 2.

The research aims to develop and evaluate a delivery model for implementing StandingTall within community aged care services. The delivery model has been designed and will be refined in co-design with aged care providers. The primary outcome will assess adoption (health care professionals are referring clients to the intervention) to the program. Secondary outcome measures include reach, effectiveness, adoption (uptake), implementation, and maintenance.

This study aims to investigate the feasibility and acceptability of patient initiated follow-up (PIFU) following surgery for low risk endometrial cancer. Who is it for? You may be eligible for this study if you are a woman aged 18 years or over who has completed definitive primary surgical treatment for endometrial endometrioid adenocarcinoma, and has been assessed by a gynaecological oncology multidisciplinary team as having low risk disease in whom adjuvant therapy is not indicated. Study details Participants will be randomly allocated to PIFU, or standard of care follow up 6-monthly with the patient's General Practitioner. In the PIFU group, participants will receive an education session at baseline regarding when and how to contact the gynaecologic oncology service. Data will be collected on how many women on PIFU refer themselves back to the clinic. All participants will be followed up at 12 months post-baseline to conduct quality of life measures and cancer recurrence rates will be assessed. It is hoped that findings from this study inform a larger trial in future to assess healthcare costs and long term cancer outcomes associated with PIFU in endometrial cancer.

The aim of this study is to assess the tolerability, safety and cost of transperineal prostate biopsy techniques in men with suspected prostate cancer. Who is this for? You may be eligible to participate in this study if you are scheduled to undergo a transperineal prostate biopsy for suspected prostate cancer, or as part of active surveillance for prostate cancer. Study details Participants who consent to participating in this study will undergo a transperineal prostate biopsy with Penthrox and local anaesthetic by a qualified Urologist at a public hospital. We will assess your pain levels during the biopsy with a visual analogue scale survey and also analyse rates of cancer detection, perioperative complications and costs. We will do this by retrospectively comparing to cohorts of patients who have undergone transperineal biopsies at the same health service prior, under general anaesthetic. Our objective is to demonstrate that transperineal prostate biopsies under local anaesthetic are comfortable for the patients, safe, and just as accurate as those performed under general anaesthetic. Further, we aim to demonstrate that it is more efficient and cost effective, therefore resulting in reduced healthcare costs and improved accessibility with less wait times for patients requiring a prostate biopsy.

The CAN-TRACK study is a closed-circuit track trial designed to assess the impact of medical cannabis on driving performance. This study aims to evaluate the cognitive, behavioural, and driving-related risks associated with the use of THC-containing medical cannabis in patients who have been using their prescribed product containing 2mg or more of THC for at least 3 months. The findings are expected to provide valuable insights into how medical cannabis influences driving safety, informing public health policies and road safety regulations.

Timely provision of analgesia in the emergency department is often challenging, especially during periods of high patient demand. This has been exacerbated by ongoing staff shortages since the COVID-19 pandemic. Although several analgesic options already exist in the emergency department setting, not all clinical scenarios are well catered for. In particular, patients who are required to undergo a painful procedure in the emergency department, such as suturing, wound debridement or reduction of a fracture, often have to wait for a considerable length of time due to lack of an available treatment space with a nitrous oxide wall outlet, inadequate staffing to provide a second clinician or inadequate fasting. Penthrox provides an alternative that may alleviate some of these issues, allowing for more timely administration than nitrous oxide and subsequently a shorter length of stay. Although a number of studies have been published comparing Penthrox with placebo, there are no good quality head-to-head studies that directly compare Penthrox with nitrous oxide.